StockTipsArenaBeta

BUY Zydus Lifesciences Limited — Vikas Salunkhe, Nirmal Bang Securities

BUYZydus Lifesciences Limited
Zydus Lifesciences share price target & all analyst calls

byVikas Salunkhe, Nirmal Bang SecuritiesHorizon: Swing (≤2wk)30 Oct 2026via CNBC Awaaz.

Entry—Next open
Target₹1,280
Total upside —
Stop loss₹1,230—
CMP₹1,245.56h ago
ActiveNA+2.77%upside left 2 wk left
Follow Vikas Salunkhe for new calls(27% target hit, 134 closed calls)Get alertsWatch ZYDUSLIFE for new buy/sell callsGet alertsSee 237 other Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 30 Oct, 10:21 pm IST
5 supporting1 neutral2 opposing
Supports the BUY call (5)

MACD above its signal line — bullish momentum

Technicals · macd·30 Oct · today

1 advisor has an active short-term BUY call on this stock, issued in the last 14 days

Advisor consensus · adjacent horizon·28 Oct · 2d ago

Zydus Lifesciences' subsidiary Zylidac Bio has partnered with Prolific Machines to scale a biologics manufacturing platform to GMP production.

BSE · Company Update·21 Oct · 1w ago

(opens in new tab)

Zydus Lifesciences received USFDA approval for Estradiol and Levonorgestrel Transdermal System, qualifying for 180-day competitive generic therapy exclusivity.

BSE · Company Update·21 Oct · 1w ago

(opens in new tab)

Zydus Lifesciences received USFDA approval for its Estradiol and Levonorgestrel Transdermal System, qualifying for 180-day competitive generic therapy exclusivity.

NSE · Press Release·21 Oct · 1w ago

(opens in new tab)
Neutral / worth noting (1)

Q2 FY27 results scheduled — board meets 04 Nov 2026

BSE · Board Meeting·In 4 days

(opens in new tab)
Weighs against the BUY call (2)

RSI at 80 — overbought territory

Technicals · rsi·30 Oct · today

Zydus Lifesciences In Focus As US FDA Flags Data Integrity, Quality Control Issues At Gujarat Plant

NewsNdtv-Profit·26 Oct · 4d ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Zydus Lifesciences

All analyst calls on Zydus Lifesciences

More from Vikas Salunkhe, Nirmal Bang Securities

Every call and its outcome